From Financial Modeling Prep: 2025-03-14 07:00:05

Harmony Biosciences, with a ROIC of 17.22%, surpasses its WACC of 8.63%, showing efficient capital use with a ratio of 1.99. Peers like Inhibrx Biosciences and Kymera Therapeutics have negative ROIC values, indicating they are not generating returns above their cost of capital. Harmony’s success lies in its effective capital utilization.

Harmony Biosciences, known for its narcolepsy treatment WAKIX, demonstrates strong financial metrics. With a ROIC of 17.22% exceeding its WACC of 8.63%, Harmony’s efficient capital utilization is evident. In contrast, competitors like Inhibrx Biosciences and Kymera Therapeutics have negative ROIC values, suggesting they struggle to generate positive returns.

In the biopharmaceutical industry, negative ROIC values are common among companies facing high R&D expenses. Vaxcyte, for example, has a ROIC of -16.16% compared to its 8.81% WACC, resulting in a negative ratio. While Harmony Biosciences excels with a positive ROIC to WACC ratio, peers like Vaxcyte still struggle to achieve profitability.

Harmony Biosciences’ positive ROIC to WACC ratio sets it apart from competitors in the biopharmaceutical sector. While peers like Inhibrx Biosciences and Kymera Therapeutics are yet to generate positive returns, Harmony’s efficient capital management positions it as a stable investment option. The company’s strong performance in this metric indicates potential for growth and stability in the market.



Read more at Financial Modeling Prep:: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) O…